Agenus (4-Antibody)

Broad platform of antibodies and vaccines targeting the immune system for cancer therapy 

Agenus is developing a clinical pipeline of proprietary cancer vaccines and monoclonal antibodies for use individually and in combination in the treatment of a range of cancers. The company has established collaborations with Merck and Incyte on some of its checkpoint modulators.

CEO  Garo Armen

www.agenusbio.com

Advent Contact  Shahzad Malik

Agenus acquired 4-Antibody, an Advent portfolio company, in 2014. Agenus is listed on NASDAQ.
Publicly Listed
26 May 2022 in Advent Life Sciences, Press Release

Advent Life Sciences Announces Growth of Investment Team with Three Senior Appointments

Press Release.   26 May 2022, London, UK: Advent Life Sciences, a leading transatlantic venture and growth investor focused on building innovative life science companies in the UK, Europe, and…
Read More
17 March 2021 in Advent Life Sciences, Press Release

Advent Life Sciences’ founded Amphista Therapeutics raises $53M in oversubscribed Series B round to advance next generation targeted protein degradation assets

Press Release.   This investment will fund Amphista Therapeutics’  growing pipeline of potent and selective bifunctional molecules, known as ‘Amphistas’ to the clinic and extend its proprietary platform. London, UK,…
Read More
12 March 2021 in Advent Life Sciences, Press Release

Advent Life Sciences Becomes Latest Partner of One Nucleus

Press Release.   Cambridge and London UK: 12th March 2021 Advent Life Sciences, one of the sector’s leading Trans-Atlantic venture investors has become the latest Partner to join One Nucleus.…
Read More
18 February 2021 in Advent Life Sciences, Press Release

Advent Life Sciences Announces Close of Two New Funds Totalling $215 million

Press Release.   18 February 2021, London, UK: Advent Life Sciences, a leading transatlantic venture investor focused on building innovative life science companies in the UK, Europe and the US,…
Read More